What is Hemispherian?
Hemispherian is at the forefront of oncology research, focusing on the development of GLIX compounds that target the TET2 enzyme. Their lead compound, GLIX1, is progressing through late-stage preclinical development for glioblastoma multiforme, a particularly aggressive form of brain cancer. Beyond therapeutic development, Hemispherian is also committed to creating a companion diagnostic tool to identify patients most likely to benefit from GLIX1 treatment, signaling a precision medicine approach to cancer therapy.
How much funding has Hemispherian raised?
Hemispherian has raised a total of $14.3M across 4 funding rounds:
Multiple Rounds
$14.3M
Angel/Seed (2022): $1.4M with participation from Meneldor
Private Equity (2022): $7.5M led by The European Innovation Council
Grant (2022): $2.5M supported by The European Innovation Council
Series A (2022): $2.9M featuring Kvantia, Kistefos, and Meneldor
Key Investors in Hemispherian
The European Innovation Council
The European Innovation Council is an entity operating within the Colleges & Universities sector, indicating a potential focus on research and development funding for innovative projects.
Meneldor
Meneldor specializes in providing investment opportunities for early-stage biotech and pharmaceutical companies, particularly those up to phase 2, suggesting a strategic interest in Hemispherian's preclinical development stage.
Kistefos
Kistefos AS is a diversified private investment company with a broad portfolio across various industries, indicating a strategic interest in Hemispherian's potential for significant market impact and growth.
What's next for Hemispherian?
The recent major strategic investment in Hemispherian signals a critical phase of scaling and advancement for the company. With a focus on late-stage preclinical development for GLIX1 and the parallel development of a companion diagnostic, this capital infusion is expected to accelerate the path towards clinical trials. The company's enterprise-level backing suggests confidence from investors in its innovative approach to targeting TET2 and addressing the unmet needs in glioblastoma treatment. Future endeavors will likely involve further R&D, regulatory submissions, and potential strategic partnerships to bring this promising therapy to patients.
See full Hemispherian company page
